Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Diasol, Inc
WARNING LETTER
•Diasol, Inc•August 19, 2025

Diasol, Inc – FDA Warning Letter, Aug 19, 2025

Record Details

The FDA issued a Warning Letter to Diasol, Inc. following an inspection from July 21 to August 19, 2025, at their Phoenix, AZ facility, which manufactures disinfectants and concentrates for hemodialysis systems. The company was cited for significant violations of the Federal Food, Drug, and Cosmetic Act and the Quality System Regulation (21 CFR Part 820) for medical devices. A primary issue involved the firm marketing unapproved solutions of Citric Acid (50% and 20%) for cleaning and disinfection of hemodialysis machines without the required FDA premarket approval or clearance, rendering these products adulterated and misbranded. Further extensive violations of Quality System Regulations included failures in: establishing adequate procedures for finished device acceptance, leading to non-compliant product specifications and untested batches; validating critical manufacturing processes such as drum cleaning, mixing, and water purification; implementing appropriate process controls for water quality and warehouse environmental conditions; maintaining equipment and facilities, with observed leaks, inoperable systems, and structural deterioration; effectively controlling nonconforming products, including a lack of proper investigation into out-of-specification results; establishing suitable complaint handling procedures, failing to classify product replacements as complaints or evaluate for Medical Device Reporting; and implementing effective Corrective and Preventive Actions, resulting in recurring deficiencies. Diasol, Inc. is required to implement comprehensive, documented corrective actions to address these systemic issues, ensuring full compliance with FDA regulations. The FDA deemed many of the company's initial responses inadequate, emphasizing the need for robust verification of all implemented changes.

Company
Diasol, Inc
Inspection date
August 19, 2025
Product type
devices
Office
Center for Devices and Radiological Health
People
  • Barbara A. Marsden (Acting Director)
  • Monica F. Abeles
View Company Profile

ID · d4a4176e-a163-4a26-b8c4-3d2153f626c6

Violation Codes10
21 CFR 803.20(c)(1)21 CFR 820.198(a)21 CFR 803.1721 CFR 82021 CFR 80321 CFR 803.17(a)(1)21 CFR 803.50(a)(2)21 CFR 803.50(a)21 U.S.C. 351(f)(1)(B)21 U.S.C. 360j(g)

Full citation text and observation details available on the Dashboard.

Other documents for Diasol, Inc
  • 483 - 2025-08-19August 19, 2025
  • 483 - 2021-06-28June 28, 2021

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Diasol, Inc
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.